Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $18.67, for a total value of $149,360.00. Following the transaction, the insider now directly owns 8,000 shares in the company, valued at approximately $149,360. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Corcept Therapeutics Incorporated (NASDAQ CORT) opened at $20.65 on Friday. The company has a market capitalization of $2,379.49, a price-to-earnings ratio of 71.21 and a beta of 1.89. Corcept Therapeutics Incorporated has a 12-month low of $6.70 and a 12-month high of $21.00.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.02). The business had revenue of $42.70 million during the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a net margin of 27.28% and a return on equity of 58.17%. The business’s revenue was up 96.8% compared to the same quarter last year. During the same period last year, the company earned $0.02 EPS. equities analysts predict that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current year.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies reissued a “buy” rating and set a $24.00 target price on shares of Corcept Therapeutics in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $21.00.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Corcept Therapeutics by 18.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,440,064 shares of the biotechnology company’s stock valued at $52,394,000 after acquiring an additional 689,554 shares during the last quarter. Renaissance Technologies LLC grew its position in Corcept Therapeutics by 44.4% in the 2nd quarter. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company’s stock valued at $31,664,000 after acquiring an additional 824,900 shares during the last quarter. State Street Corp grew its position in Corcept Therapeutics by 26.1% in the 2nd quarter. State Street Corp now owns 2,028,013 shares of the biotechnology company’s stock valued at $23,931,000 after acquiring an additional 420,139 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Corcept Therapeutics by 41.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,204,325 shares of the biotechnology company’s stock valued at $23,242,000 after acquiring an additional 355,006 shares during the last quarter. Finally, Prudential Financial Inc. grew its position in Corcept Therapeutics by 74.1% in the 3rd quarter. Prudential Financial Inc. now owns 1,102,483 shares of the biotechnology company’s stock valued at $21,278,000 after acquiring an additional 469,260 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/corcept-therapeutics-incorporated-cort-insider-robert-s-fishman-sells-8000-shares/1805712.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.